Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
CME Group Inc.'s published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $109.6B | |
|---|---|---|
| Revenue (ttm) | 7B | |
| Net income (ttm) | 4.4B | |
| EPS (ttm) | $12.2 | |
| Shares out | 357.9M | |
| P/E (trailing) | 24.1x | |
| P/E (forward) | 23.5x | |
| Dividend | $11.4 (3.86%) | |
| Volume | 996,802 | |
| Beta | 0.27 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $4.69B | $5.02B | $5.58B | $6.13B | $6.52B | +8.6% |
| Gross profit | $3.85B | $4.27B | $4.75B | $5.28B | $5.61B | +9.9% |
| Operating income | $3.54B | $3.65B | $4.31B | $4.70B | $5.50B | +11.7% |
| Net income | $2.64B | $2.69B | $3.23B | $3.53B | $4.07B | +11.5% |
| EPS (diluted) | $7.29 | $7.40 | $8.86 | $9.67 | $11.16 | +11.2% |
| EBITDA | $3.93B | $4.02B | $4.67B | $5.04B | $5.83B | +10.4% |
| R&D | — | — | — | — | — | — |
| SG&A | $151.7M | $137.4M | $144.4M | $132.7M | $150.5M | -0.2% |
Recent company headlines from major financial publishers.
Prolonged macroeconomic uncertainty, fluctuating interest rates, and geopolitical shifts drive record hedging activity and volume across CME's product suite. The company pushes through pricing increases uninhibited, scaling margins further and driving low-double-digit EPS growth.
CME Group benefits from near-monopoly network effects in interest rate, energy, and agricultural derivatives. Its vertically integrated clearinghouse acts as a massive competitive barrier. As a mature compounder, it generates extraordinary margins and massive free cash flow.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.1% | $313 | $347 | $389 | $444 | $457 |
| 8.1% | $261 | $285 | $313 | $347 | $389 |
| 9.1% | $224 | $241 | $261 | $285 | $313 |
| 10.1% | $196 | $209 | $224 | $241 | $261 |
| 11.1% | $175 | $185 | $196 | $209 | $224 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |